Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Read in Swedish

Vitrolife AB (publ): Vitrolife announces changes to the executive management team after the acquisition of Igenomix

13:00 / 1 December 2021 Vitrolife Press release

As announced on 30 November, 2021, Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.

The executive management team will from 1 January, 2022, consist of:
Thomas Axelsson, President and Chief Executive Officer
Group Functions:
Francisco Jiménez, SVP Strategy & Corporate Development
Karin Koritz Russberg, SVP HR & Sustainability
Carlos Simón, Chief Scientific Officer
Patrik Tolf, Chief Financial Officer
Business Areas:
Claus Bisgaard, SVP Vitrolife Technology
Ricardo Capella, SVP Igenomix
Maria Forss, SVP Vitrolife Consumables
Business Functions:
Rickard Ericsson, SVP Vitrolife Sales & Marketing
Francisco Rodriguez, SVP Igenomix Affiliates

Gothenburg, December 1, 2021
Thomas Axelsson, CEO


Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women's health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:

Show as PDF

Show original from Cision


This information was distributed by Cision